Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robert A. Dillman"'
Autor:
Robert A. Dillman, John P. Micha, William A. Peters, Beth Y. Karlan, Michael R. Smith, Charles W. Drescher, John V. Brown, Mark A. Rettenmaier
Publikováno v:
Gynecologic Oncology. 79:495-498
Objective. This trial was undertaken to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of topotecan that can be administered for 3 days q 21 days. A 3-day schedule is more convenient and less expensive than standard 5-day
Autor:
John V. Brown, John P. Micha, Pamela Fraser, Connie L. Birk, Robert O. Dillman, Mark A. Rettenmaier
Publikováno v:
Gynecologic oncology. 69(2)
Paclitaxel is one of the most active chemotherapy agents for the treatment of ovarian and other gynecologic cancers. Hypersensitivity reactions (HSR) remain one of the major clinical concerns in the use of paclitaxel. This report deals with 183 conse
Autor:
John P. Micha, Kathleen Culkin, Connie L. Birk, Robert A. Dillman, Mark A. Rettenmaier, John V. Brown
Publikováno v:
Gynecologic oncology. 68(2)
Objective. The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer. Methods. Thirty patients with s